Hikma licenses Chiesi Group’s respiratory and neonatal products for Egyptian market

Corporate, Press Release

Hikma licenses Chiesi Group’s respiratory and neonatal products for Egyptian market

London, 13 January 2020 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P) the multinational pharmaceutical company, today announced an exclusive licensing and distribution agreement with Chiesi Farmaceutici, a research-focused international pharmaceutical Group (Chiesi Group), headquartered in Italy.

The agreement provides Hikma with exclusive rights to commercialise 11 of Chiesi’s leading products in Egypt, including currently marketed and pipeline products. This builds on Hikma’s existing partnership with Chiesi in Morocco and adds a range of innovative products to its Egyptian portfolio, including Foster®, Foster Nexthaler®, Trimbow® and Curosurf®.

Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA said, “We are very pleased to be partnering with Chiesi to commercialise a range of specialty products, primarily in respiratory and neonatal therapeutic areas, in Egypt.  This supports our strategy of working with global partners to strengthen our portfolio in growing therapeutic categories.  In particular, this agreement enables us to meet the needs of a growing number of patients suffering from asthma and COPD in Egypt and improve their access to high-quality medicines.” 

Ugo Di Francesco, CEO of Chiesi Group commented: “We are really proud to have strengthened our strategic partnership with Hikma. This will allow us to increase the availability of our main therapeutic solutions in the respiratory and neonatology fields to Egyptian patients. The agreement highlights our continued progress against Chiesi Group’s main mission: addressing population health needs around the world.”